Phase 4 N=88 Randomized Triple-blind Treatment

Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence

Hypotrichosis

Bottom Line

View on ClinicalTrials.gov: NCT01448525 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

May 2013

Primary outcome: Primary: Percentage of Participants Who Are Satisfied or Very Satisfied With Their Eyelashes Overall — 67.4; 7.1 Percentage of participants

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: bimatoprost ophthalmic solution 0.03% (Drug); bimatoprost vehicle solution (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: Female
Sponsor: Allergan
Primary completion: Apr 2012

Outcome Measures

Outcome	Result	p-value
PRIMARY Percentage of Participants Who Are Satisfied or Very Satisfied With Their Eyelashes Overall	67.4; 7.1	—
SECONDARY Percentage of Participants With at Least a 1-Grade Increase in the Global Eyelash Assessment (GEA) Score	72.1; 19.0	—

Summary

The purpose of this study is to determine patient satisfaction with LATISSE® treatment for increasing eyelash prominence.

Eligibility Criteria

Inclusion Criteria

Have inadequate eyelashes
Never used prescription eyelash growth products

Exclusion Criteria

No visible eyelashes
Permanent eyeliner or eyelash implants
Semi-permanent eyelash tint, dye, or extensions within 3 months
Over-the-counter eyelash growth products within 6 months
Any disease, infection or abnormality of the eye or area around the eye
Eye surgery within 3 months, or the anticipated need for eye surgery during the study
Unable or unwilling to keep contact lenses out during drug application and for 30 minutes after application

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01448525). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.